ASTCT Pharmacy SIG Journal Club - June 2026 - Enduring Session

The ASTCT Pharmacy SIG June 2026 Journal Club aired on Wednesday, June 10. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the June Journal Club session, Drs. Dugas and Kanchan will presented two articles related to:

• Brexucabtagene autoleucel in BTKi‑naive relapsed/refractory mantle cell lymphoma
• Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide maintenance post‑transplant in multiple myeloma

Presenters & Articles:

Logan Dugas, PharmD

PGY-2 Pharmacy Resident

Moffitt Cancer Center

Article: Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Nidhi Kanchan, PharmD

PGY-2 Pharmacy Resident

UC San Diego Health

Article: Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Recognize post-ASCT maintenance strategies that have been studied in multiple myeloma.
• Report efficacy and safety of KRd as a risk-stratified maintenance approach.
• Discuss the application of KRd maintenance following transplant in newly diagnosed multiple myeloma.
• Review current treatment recommendations and sequencing of therapy for relapsed/refractory mantle cell lymphoma, including the role of BTK inhibitors.
• Evaluate safety and efficacy of brexucabtagene autoleucel in BTKi-naive patients with relapsed/refractory mantle cell lymphoma based on the primary analysis of ZUMA-2 Cohort 3.
• Summarize the role of brexucabtagene autoleucel in earlier lines of therapy for patients with high-risk relapsed/refractory mantle cell lymphoma.

This activity will expire on June 9, 2027.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session can be found here.